Introduction
It has been widely accepted that adequate calcium intake is critical for development and maintenance of bone health, particularly in children and elderly adults. In addition to a pivotal role in skeletal metabolism, the potential effects of calcium on non-skeletal health outcomes have received growing attention, [1] among which the effect of calcium intake on cardiovascular disease (CVD) is a subject of intense interest. In vitro and in vivo experimental studies provide evidence for the involvement of calcium in multiple physiologic processes that may modify the function or structure of the cardiovascular system. Some, but not all, epidemiologic studies report associations between inadequate calcium intake and both an adverse CVD risk factor profile and increased risk of CVD events. Moreover, several completed randomized clinical trials that have evaluated the risks and benefits of calcium supplementation on bone mineral density and or fracture incidence offer valuable, though preliminary, data regarding possible effects of calcium supplements on risk of CVD. Since many generally healthy US adults take supplemental calcium for bone health, [2] it is important to better understand the balance of risks and benefits related to calcium supplement use. This review covers experimental, epidemiologic, and clinical evidence regarding the role of calcium intake in the development of CVD among adults.
Methods

Data Sources and Literature Search
We searched the published literature for studies on calcium and CVD events between 1966 to 1 September 2010, using MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. The search terms for calcium included calcium intake, calcium supplement, calcium carbonate, and calcium citrate. The search terms for CVD included cardiovascular disease, ischemic heart disease, coronary artery disease (CAD), cardiovascular mortality, myocardial infarction (MI), and stroke. The literature search was restricted to English-language articles, human studies, and adult subjects aged ‡19 years. The same search strategy was applied to each database. We also manually searched reference lists of the identified articles for additional studies.
Study Selection and Data Extraction
Two investigators (Drs Wang and Sesso) independently reviewed all identified articles. We excluded ecological, crosssectional, and retrospective case-control studies due to concerns for temporality and reverse causation. Based upon review of the abstract, we also excluded case reports, studies of children and adolescents, and studies that did not assess levels of dietary calcium, calcium supplement use, or serum or plasma calcium levels. Articles that passed abstract screening were retrieved for a full-text review. We then further excluded review articles, editorials, the studies that did not compare risk of CVD between different levels of dietary, supplemental, or circulating calcium and the studies that did not ascertain CVD events including CVD death, non-fatal CAD or MI, and nonfatal stroke. One investigator (Dr Wang) extracted key information from selected studies to summary tables. Data extracted for observational studies included country, study design, sample size, participant characteristics (including age, gender, and comorbid conditions), dietary, supplemental, or blood calcium examined, CVD endpoints, follow-up period, and main study findings. Data extracted for randomized trials included country, sample size, participant characteristics, dosage and duration of calcium supplement, follow-up period, primary endpoint(s), and main findings for CVD outcomes. For separate publications from the same study population, we considered each publication as an individual study. We did not contact authors for missing data.
Data Synthesis and Analysis
For each individual study identified from the literature search, we extracted the reported relative risks (RRs) and 95% confidence intervals (CIs) of CVD events across categories of dietary calcium or calcium supplement use. When the RRs from individual studies could be combined, we conducted metaanalyses. The RRs used in the meta-analysis were those adjusted for covariates as comprehensively as possible. For the studies that did not report RRs but reported CVD event rates, we calculated the unadjusted RRs and 95% CIs. [3] When the RRs from individual studies could be combined, we conducted meta-analyses. The pooled RR and 95% CIs were calculated by the random-effects method of DerSimonian and Laird [4] using STATA statistical software (version 7.0, STATA Corp., College Station, TX, USA).
Metabolism and Physiologic Significance of Calcium
Calcium is quantitatively the most abundant mineral in the human body. An average adult's body typically contains about 1.0-1.5 kg calcium, 99% of which resides in bones and teeth. Besides the structural role in the skeleton, calcium is a vital electrolyte that is required for many critical biologic functions, including muscle contraction, vascular tone, nerve transmission, and many enzyme-mediated processes. [5] Intracellular calcium ion levels (Ca 2+ ) are typically 10 3 -to 10 4 -fold lower than the extracellular level. [6] When the cell is stimulated, calcium enters the cell from extracellular compartments to activate the proper proteins in the signal transduction pathway. Upon the completion of the response, calcium is pumped outside the cell or into intracellular storage to await the next activation cycle. Calcium homeostasis is tightly controlled by the calciotropic hormones: vitamin D, parathyroid hormone, and calcitonin. [7] These hormones regulate calcium absorption from intestine, excretion or re-absorption from kidney, and deposition or release from bone. As a result, the circulating level of calcium is usually maintained constant in the range of 1.0-1.2 mmol L. [8] Unless there is prolonged and severe calcium deficiency, the calcium level in blood is rarely compromised. Excessively high levels of calcium in blood -known as hypercalcemia -rarely occur due to excessive dietary or supplemental calcium intake, but more commonly result from primary hyperparathyroidism or malignancy. [8] Hypercalcemia can cause many medical disorders, such as renal insufficiency, vascular and soft tissue calcification, and kidney stones.
Calcium Intake in the US Population
Since calcium cannot be produced in humans and its excretory conservation is weak, sufficient daily intake is required to maintain adequate calcium supply in each individual. The amount of daily calcium needs varies by age. The National Institutes of Health (NIH) recommends a daily intake of 1000 mg for men between 25 and 65 years of age. [9] The same amount is also recommended for women between 25 and 50 years, except for pregnant or lactating women or post-menopausal women not on estrogen replacement therapy, for whom 1500 mg day is recommended. [9] For all men and women over 65 years of age, the NIH recommends daily calcium intake to be 1500 mg. [9] The US Institute of Medicine (IOM) recently updated the dietary reference intakes for calcium and recommends intake of 1000 mg day for all adults aged 19 through 50 years and for men until age 70 years, and of 1200 mg day for women starting at age 51 years and both men and women aged >70 years. [8] Calcium-rich foods (milk and other dairy products) are the preferred source of calcium intake due to higher absorption efficiency, [10] while calcium supplementation is an alternative means to reach optimal intake for those who cannot obtain adequate calcium through diet alone.
Despite the well-recognized benefits of calcium on bone health, the daily calcium intake in the general US population remains below current recommendations, particularly among elderly adults and women. [8] The mean estimated dietary intake of calcium was 952 and 872 mg day, respectively, for men aged 51-70 years and ‡71 years, and 788 and 750 mg day, respectively, for women in the same age groups. [8] More than half of American men older than 50 years and American women in all age groups fail to meet the recommended intake of calcium from food sources; only less than 25% of women aged >50 years achieved the recommended intake level from diet. [8] Because a large number of US adults, mostly older women, take calcium supplements to increase total calcium intake, [2] it is also necessary to consider the health effects of calcium supplement use.
Potential Effect of Calcium on Cardiovascular Disease Risk
Laboratory studies have shown multiple biologic mechanisms through which calcium may affect the risk of developing CVD (table I) . When consumed in large amounts, calcium binds to fatty acids and bile acids in the intestine to form insoluble soaps, Table I . Potential effects and mechanisms of calcium in pathogenesis of cardiovascular disease
Effect
Biologic mechanisms
Favorable cholesterol changes
Binds to fatty acids and bile acids in intestine to form insoluble soaps, increases lipid excretion, and decreases amount of lipids entering enterohepatic circulation [11, 12] BP lowering Down-regulates activity of renin-angiotensin system, [13] improves sodium-potassium balance, [14] and suppresses vascular smooth muscle tone [15] Anti-obesity effect Reduces adipocyte intracellular calcium, inhibits fatty acid synthase, and activates lipolysis [16] Improvement of insulin secretion
Maintains the balance between extracellular and intracellular calcium pools of pancreatic b cells [17] Enhancement of insulin sensitivity Improves insulin signal transduction in primary insulin target tissues [18] [19] [20] Improvement in inflammatory profile
Inhibits cytokine-induced apoptosis [21] Anti-thrombotic property
Reduces platelet intracellular free calcium load and inhibits platelet aggregation [22] Augmentation of vasorelaxation Enhances hyperpolarization by opening of calcium-activated potassium channels, increases sensitivity to nitric oxide, and decreases production of superoxide and vasoconstrictor prostanoids [23] [24] [25] Vascular calcification Calcium deposition in atherosclerotic lesions [26] subsequently decreases fatty acid absorption and lowers blood cholesterol levels. [11, 12] Dietary calcium also down-regulates the activity of the renin-angiotensin system, [13] improves sodiumpotassium balance, [14] and decreases vascular smooth muscle tone, [15] which all contribute beneficially to BP regulation. High calcium intake suppresses the influx of calcium from outside the cells. In adipocytes, reductions in intracellular calcium inhibit fatty acid synthase and activate lipolysis, potentially leading to an anti-obesity effect. [16] In pancreatic b-cells, insulin secretion is a calcium-dependent process that will be compromised when intracellular calcium is either too high or too low. [17] An optimal range of intracellular calcium is also required for insulin-mediated activities in liver, skeletal muscle, and adipose tissues. [18, 19, 27, 28] Maintaining relatively low intracellular calcium levels in these target organs has favorable effects on insulin signal transduction [18, 20] and peripheral insulin sensitivity. [19, 20] In addition, low intracellular calcium inhibits platelet aggregation, [22] attenuates cytokine-induced inflammation, [21] and augments vascular relaxation. [23] [24] [25] Lastly, the cardiovascular benefits of greater calcium consumption may be indirectly mediated through induced activities of the calciotropic hormones. [16] On the other hand, excessively high calcium intake may also lead to hypercalcemia and vascular calcification, thereby raising CVD risk. [26] 6. Epidemiologic Studies of Dietary Calcium Intake and Cardiovascular Disease Risk As reviewed before, [5] ecologic studies and cross-sectional studies found both positive and inverse correlations between higher calcium intake and CVD risk factors, including high BP, dyslipidemia, diabetes, and obesity. Reverse causation is a concern in these studies, and thus prospective cohort studies provide more valuable information in assessing the potential effects of long-term dietary and supplemental calcium intake on subsequent development of CVD (table II) . Among 34 486 US post-menopausal women in the IWHS (Iowa Women's Health Study), reduction in CAD mortality was observed with high calcium intake: the relative risk (RR) of CAD mortality in the highest versus the lowest quartile of calcium intake was 0.67 (95% CI 0.47, 0.94) for total calcium intake and 0.63 (95% CI 0.40, 0.98) for dietary calcium intake without supplements. [32] Among 23 366 participants in a population-based cohort of Swedish men, higher dietary calcium was associated with a borderline significant lower rate of CVD mortality during 10 years of follow-up (RR in the highest compared with the lowest tertile of intake: 0.77; 95% CI 0.58, 1.01). [39] However, the same association between dietary calcium and CAD mortality was not found in cohorts of Dutch civil servants, [29] US male health Calcium Intake and Risk of Cardiovascular Diseaseprofessionals, [34] and Japanese men and women. [36] There was also no association between dietary calcium intake and subsequent incidence of total CAD (including non-fatal MI and CAD death) in US, [34] Finnish, [35] and Japanese [38] cohorts. In the HHP (Honolulu Heart Program), the RR for thromboembolic stroke in the lowest quartile of dietary calcium intake compared with the highest quartile was 1.8 (95% CI 1.1, 2.9). [30] In the NHS (Nurses' Health Study), the RR for incident ischemic stroke in the highest quintile of dietary calcium compared with the lowest quintile was 0.73 (95% CI 0.53, 1.01) [p-value for trend = 0.04]. [33] Similar inverse associations between dietary calcium intake and incident stroke were also observed in two Japanese cohorts [36, 38] but not in the HPFS (Health Professionals Follow-up Study) [31] or the ATBC (Alpha-Tocopherol, Betacarotene Cancer Prevention) study.
[37] When we conducted meta-analyses to combine these data, the pooled RR of CVD comparing the highest to the lowest level of dietary calcium intake was 0.92 (95% CI 0.80, 1.07) for any CAD and 0.86 (95% CI 0.69, 1.06) for any stroke (figure 1).
Epidemiologic Studies of Calcium Supplement Use and Cardiovascular Disease Risk
We are aware of five prospective studies that have specifically examined calcium supplement use in relation to risk of CVD, of which four studies found no significant associations (table III) . In the HPFS, comparing men who took the highest dose of calcium supplement (median of 1000 mg day) with nonusers, the RRs were 0.87 (95% CI 0.64, 1.19) for total CAD, 1.02 (95% CI 0.71, 1.46) for non-fatal MI, and 0.61 (95% CI 0.34, 1.10) for CAD death; [34] comparing men who took ‡400 mg day of calcium supplements with non-users, the RR of stroke was 0.88 (95% CI 0.60, 1.27). [31] In the IWHS, the RR of CAD mortality comparing women taking ‡500 mg day of calcium supplements versus non-users was 0.88 (95% CI 0.64, 1.23). [32] In the NHS, the RR of stroke for women taking ‡400 mg day of calcium supplements versus non-users was 0.75 (95% CI 0.56, 1.01). [33] Only one recent study, KORFPS (Kuopio Osteoporosis Risk Factor and Prevention Study), of 10 555 Finnish Stroke Author (year), study Van der Vijver et al. [29] (1992), Dutch Study (men)
Van der Vijver et al. [29] (1992), Dutch Study (women)
Bostick et al. [32] (1999), IWHS Al-Delaimy et al. [34] (2003), HPFS Marniemi et al. [35] (2005), Finnish Study Umesawa et al. [36] (2006), JACC (men)
Umesawa et al. [36] (2006), JACC (women)
Umesawa et al. [38] (2008), JPHC Pooled Author (year), study
Abbott [30] (1996), HHP Ascherio et al. [31] (1998), HPFS Iso et al. [33] (1999), NHS Marniemi et al. [35] (2005), Finnish Study Umesawa et al. [36] (2006), JACC (men)
Umesawa et al. [38] (2008), JPHC Larsson et al. [37] women aged 52-62 years old, found an increased risk of CAD with the use of calcium supplements or calcium plus vitamin D supplements. During an average of 6.6 years of follow-up, the RR of CAD comparing women who used calcium or calcium plus vitamin D supplements with non-users was 1.24 (95% CI 1.02, 1.52). [40] Combining these data, the pooled RR of CVD in the highest versus the lowest dose of calcium supplement use was 1.01 (95% CI 0.78, 1.30) for CAD and 0.80 (95% CI 0.63, 1.01) for stroke (figure 2).
Epidemiologic Studies of Blood Calcium Level and Cardiovascular Disease Risk
Since the blood concentration of calcium is controlled by calciotropic hormones, calcium intake only modestly changes blood calcium levels. We found only few studies that examined the association between circulating calcium levels and CVD. In a cohort of 2183 middle-aged Swedish men, serum calcium was an independent risk factor for MI during an 18-year follow-up. The estimated incidence of MI varied from 0.06 to 0.15 over the range of mean -2 standard deviations (SDs) of serum calcium levels. The odds ratio for MI corresponding to the difference between the upper and lower end of the range was 2.33 (95% CI 1.21, 4.51). [41] In the ARIC (Atherosclerosis Risk in Communities) study, by contrast, serum calcium levels were not associated with risk of CAD but were positively associated with risk of stroke over 12.6 years' follow-up. The hazard ratio per 0.4 mg dL (0.1 mmol L) increase in serum calcium was 1.01 (95% CI 0.96, 1.06) for CAD and 1.16 (95% CI 1.07, 1.26) for stroke. [42] These data seem to suggest a possible adverse effect of serum calcium levels on the risk of CVD, but the evidence is limited and weak. In contrast to these findings, in a Finnish cohort study of elderly men and women with follow-up up to 10 years, serum levels of calcium were not significantly associated with risk of either acute MI or stroke. [35] 
Effect of Calcium Supplementation on Cardiovascular Disease Outcomes in Randomized Clinical Trials
To our knowledge, no randomized clinical trial has specifically tested the effect of calcium supplementation on CVD as its [43] A randomized, double-blind, placebo-controlled trial of 1460 Australian women reported a RR of 1.12 (95% CI 0.77, 1.64) for clinically diagnosed CAD comparing women taking calcium carbonate 1200 mg day (given in two divided doses) versus those taking placebo. [44] A more recent report from the same trial extended analyses to examine the combined endpoint of mortality or first hospitalization due to CVD after 5 years of randomized treatment plus 4.5 years of post-trial follow-up. The RR was 0.94 (95% CI 0.69, 1.28) at the conclusion of treatment, and 0.92 (95% CI 0.74, 1.15) after all 9.5 years of follow-up. [50] In another trial in New Zealand, 1471 healthy post-menopausal women were randomized to take 1 g day of calcium citrate or placebo. After 5 years' treatment and follow-up, women in the calcium group experienced more adjudicated MI events and composite CVD endpoints including MI, stroke, and sudden death than women in the placebo group. [45] However, when unreported events identified from the national database of hospital admissions were added, the increased RR in the calcium group was no longer significant (RR = 1.49; 95% CI 0.86, 2.57 for MI; and RR = 1.21; 95% CI 0.84, 1.74 for composite CVD). Finally, a trial of 323 healthy men ‡40 years of age from New Zealand randomized participants to take calcium citrate 600 mg day, calcium citrate 1200 mg day, or placebo. The composite endpoint of vascular events including angina, MI, sudden death, and coronary revascularization were more common in the calcium supplement group versus the placebo group. Because the vascular event rates were very low, however, the statistical power to detect any difference was small. [46] Some trials evaluated the cardiovascular effects of combined calcium and vitamin D supplementation. In a multicenter trial conducted in France, 192 elderly women with vitamin D insufficiency (serum 25-hydroxyvitamin D £12 ng mL) were randomized to receive either a combination tablet containing calcium carbonate 1000 mg and vitamin D 3 800 IU daily, or a placebo tablet. Six patients in the active supplement group and five patients in the placebo group reported the occurrence of a CVD event during 1 year of follow-up. [47] Among 36 282 postmenopausal women in the WHI (Women's Health Initiative), daily supplementation of 1000 mg of calcium carbonate and 400 IU of colecalciferol (vitamin D 3 ) did not alter the risk of CVD during 7 years of follow-up (RR = 1.05; 95% CI 0.91, 1.20 for non-fatal MI; RR = 1.01; 95% CI 0.79, 1.29 for CAD death; and RR = 0.95; 95% CI 0.82, 1.10 for stroke). [48] In another randomized trial of 1179 community-dwelling healthy postmenopausal women, there was no significant difference in MI or other vascular events after 4 years' supplementation with either vitamin D (1000 IU day) plus calcium (as calcium citrate 1400 mg day or calcium carbonate 1500 mg day) or calcium alone compared with placebo. [49] When the two calcium treatment groups were combined, the vascular event rate was 4.76 1000 person-years in the supplement group and 6.94 1000 person-years in the placebo group.
When we combined the data from these randomized trials, the pooled RRs of CVD were 1.14 (95% CI 0.92, 1.41) for calcium supplements versus placebo and 0.99 (95% CI 0.79, 1.22) for combined calcium plus vitamin D supplements versus double placebos (figure 3).
Discussion
Experimental studies have demonstrated that calcium is involved in multiple physiologic processes potentially related to Bostick et al. [32] (1999), IWHS Al-Delaimy et al. [34] (2003), HPFS Pentti et al. [40] (2009), KORFPS Pooled Author (year), study
Ascherio et al. [31] (1998), HPFS Iso et al. [33] the development of CVD. There have also been several epidemiologic studies examining dietary and supplemental calcium intake in relation to CVD risk, with considerable heterogeneity in study design, participant characteristics, and potential for confounding. Randomized trials specifically designed to evaluate the cardiovascular effects of short-and long-term calcium CAD = coronary artery disease; CVD = cardiovascular disease; M = men; MI = myocardial infarction; RR = relative risk; W = women.
supplementation remain lacking; current available data is primarily derived from secondary analyses of existing trials. In assessing the totality of evidence to date, it appears that calcium intake, either from diet or from supplements, has little or no effect on CVD risk. Pooled analyses combining data from several large-scale, population-based, prospective cohort studies showed a nonsignificant inverse association of dietary calcium intake with incident CAD and incident stroke. A seemingly stronger association with risk of stroke might be attributed to an established BP-lowering effect of dietary calcium. [51] Fewer studies have examined the association between calcium supplement use and incident CVD. The generally null findings noted to date suggest that calcium supplements are unlikely to confer a strong effect on CVD risk. KORFPS [40] was the only study that reported a significantly increased risk of CAD among users of calcium supplements versus non-users. [40] Of note, in this study the mean dietary calcium intake from liquid milk products and cheese was 773.8 mg day for calcium supplements users and 818.2 mg day for non-users. Although the study did not determine the daily dose of calcium supplements, total calcium intake likely exceeded the upper limit of 2000 mg day by NIH [9] and IOM guidelines [8] for participants with high habitual intake of both dietary and supplemental calcium, and these individuals might be at risk for hypercalcemia and its complications. In addition, since this study did not separate calcium and calcium plus vitamin D supplement users, it is not clear whether the increased CAD risk is specifically due to calcium or vitamin D.
There are some discrepancies in our findings on dietary versus supplemental calcium intake in association with CVD risk. This difference has been attributed in part to their different impact on circulating calcium. [52] For calcium supplements, usually taken on their own without food, there would be an immediate and sizable increase in blood calcium levels within a couple of hours after intake, and calciotropic hormone secretion and bone resorption may be affected. [53] In contrast, calcium from foods, typically during a mixed meal, will be absorbed slowly over several hours. This absorption process is less likely to cause a detectable change in blood calcium levels, and the metabolic response will vary according to simultaneous ingestion of other nutrients. [54] Since available studies on blood calcium in association with risk of CVD are very limited and inconclusive, more studies are needed to provide further insight into a complex relationship between intake, metabolism, and biologic effect of calcium on the pathogenesis of CVD.
Clinical trial data on the effect of calcium supplementation on CVD risk are limited to secondary analyses. Following the first original study that raised concerns about a possible adverse cardiovascular effect of calcium supplementation, [45] a recently published meta-analysis by Bolland et al. combined data from a total of 15 eligible clinical trials and investigated whether calcium supplements increase the risk of CVD events. [55] In the analysis of five trials with patient level data, the RR of MI for participants allocated to calcium supplementation compared with those allocated to placebo was 1.31 (95% CI 1.02, 1.67). The corresponding RRs for stroke, a composite endpoint (of MI, stroke, or sudden death), and all-cause mortality were 1.20 (95% CI 0.96, 1.50), 1.18 (95% CI 1.00, 1.39), and 1.09 (95% CI 0.96, 1.23), respectively. The analysis of trial level data showed similar results, with a pooled RR for MI of 1.27 (95% CI 1.01, 1.59). The authors concluded that calcium supplements (without coadministered vitamin D) are associated with an increased risk of MI and suggested a reassessment of calcium supplement use.
Although the randomized, controlled trial design provides the strongest support for potential causality, post hoc analyses of secondary endpoints as presented in the meta-analysis by Author (year), country Baron et al. [43] (1999), US Prince et al. [44] (2006), Australia
Bolland et al. [45] Brazier et al. [47] (2005), France
Hsia et al. [48] (2007), US Lappe and Heaney [49] Relative risk (95% CI) comparing the treatment vs the placebo group Fig. 3 . Meta-analysis of randomized controlled trials of calcium supplementation (with and without vitamin D) that reported the cardiovascular events in the treatment group vs respective placebos. CI = confidence interval; RR = relative risk. The unadjusted RR was calculated de novo for studies by Baron et al., [43] Brazier et al., [47] and Lappe et al. [49] using reported event rate in each treatment group.
Bolland et al. [55] should be interpreted with caution. First, none of the included trials was specifically designed to test the effect of calcium supplementation on risk of CVD, and the numbers of CVD events in many trials were too small to draw clinically meaningful conclusions. Second, CVD events were not prespecified endpoints in most trials and therefore were not systematically ascertained. Only two of the 15 trials had CVD events adjudicated by blinded investigators. Third, not a single trial included in this meta-analysis reported a significant difference in CVD events between calcium and placebo groups, but only the pooled RR showed a statistically significant effect. Conclusion of this meta-analysis also heavily depends on unpublished data, which can not be evaluated rigorously. Fourth, the combined trial data seem to suggest that calcium supplements increase the risk of MI, but not the risk of stroke or allcause mortality. The biologic mechanisms explaining this event-specific effect remain unclear. Taking these limitations together, currently available evidence from clinical trials does not definitively indicate an adverse effect of calcium supplementation on risk of CVD.
The report recently released by IOM [8] on dietary reference intakes for calcium and vitamin D cited a vast body of evidence for a role of calcium in promoting skeletal growth and maintenance. However, the evidence for any benefits of calcium beyond bone health remains insufficient. Though the report noted that once intake of calcium surpasses 2000 mg per day for both men and women aged ‡51 years the risk for harm may increase, it is premature to make definitive statements about the cardiovascular effects associated with high intake of calcium. Our review of epidemiologic studies and clinical trials supports the IOM report. Future studies need to include not only more prospective cohorts but also randomized trials specifically designed to evaluate the risks or benefits of calcium supplementation on CVD outcomes as the primary pre-specified endpoint.
